SURAKSHA · Healthcare · Diagnostics & Research
Composite scorecard: 44/100 — Quality 65 · Valuation 39 · Momentum 4
| Share price | ₹258.10 |
| Market cap | ₹1,376 Cr |
| P/E ratio | 42.6 |
| P/B ratio | 5.6 |
| ROCE | 14.7% |
| Dividend yield | 0.19% |
| Book value | ₹47.17 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹310 Cr | ₹31 Cr | 31.0% |
| 2025 | ₹252 Cr | ₹31 Cr | 33.0% |
| 2024 | ₹219 Cr | ₹23 Cr | 33.0% |
| 2023 | ₹190 Cr | ₹6 Cr | 25.0% |
| 2022 | ₹223 Cr | ₹24 Cr | 22.0% |
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises